Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 1998

View Archived Issues

Labopharm refocuses strategy, reports clinical progress

Ferulinolol, a highly selective beta1-adrenoceptor blocker

Ivax announces name change and restructuring

LXR Biotechnology implements strategic development plan

FUB-181 shown to improve learning and memory in mice

AMBI reports results confirming chromium picolinate's role in fat loss

Pentoxifylline as an effective treatment for chronic ulceration in HIV patients

First report of efficacy for a CCR5 antagonist in an animal model of HIV infection

Antiretroviral DAD isosteres and HIV protease inhibitors claimed by HHS

Abgenix and Genentech expand collaboration

Novel antitumor agents prepared at Kanebo

Daiichi's new antibacterial agents

Potent and selective D4 receptor ligands disclosed by Sumitomo

Kyorin presents bronchodilating PDE inhibitors

Kissei investigates compounds for preventing abortion, premature birth

JT develops more potent JTT-501 derivatives

Tridemethylthiocolchicine analogues as selective topoisomerase II inhibitors

Chugai begins clinical testing of prokinetic agent

Efavirenz shines at world AIDS conference

New oxytocin antagonist for both parenteral and oral administration developed at Merck & Co.

Novel monoamine reuptake inhibitor for Parkinson's under investigation at Knoll

U.S. approval for Maxalt

Centocor receives complete review letter for infliximab

First 10-day treatment for H. pylori infection approved by FDA

Combination of MS-818 and bFGF enhances neuronal activity

EPC-K1 inhibits striatal dopamine release in rat model of ischemia

HMR introduces Refludan in U.S.

New findings indicate that treatment guidelines should be modified for HIV-positive women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...